NEOS Investment Management LLC Buys 6,721 Shares of IDEXX Laboratories, Inc. $IDXX

NEOS Investment Management LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 60,354 shares of the company’s stock after acquiring an additional 6,721 shares during the period. NEOS Investment Management LLC’s holdings in IDEXX Laboratories were worth $31,773,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IDXX. iSAM Funds UK Ltd purchased a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $295,000. Proficio Capital Partners LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at $383,000. Grandeur Peak Global Advisors LLC raised its position in shares of IDEXX Laboratories by 21.4% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 2,229 shares of the company’s stock worth $1,173,000 after purchasing an additional 393 shares during the last quarter. Headlands Technologies LLC boosted its stake in IDEXX Laboratories by 46.0% in the 2nd quarter. Headlands Technologies LLC now owns 2,133 shares of the company’s stock worth $1,123,000 after purchasing an additional 672 shares in the last quarter. Finally, Two Sigma Securities LLC boosted its stake in IDEXX Laboratories by 166.0% in the 2nd quarter. Two Sigma Securities LLC now owns 2,636 shares of the company’s stock worth $1,388,000 after purchasing an additional 1,645 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Citigroup raised their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Barclays decreased their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, UBS Group increased their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $535.38 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The company has a 50 day moving average price of $558.27 and a 200-day moving average price of $570.47. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The firm has a market capitalization of $42.18 billion, a PE ratio of 37.65, a P/E/G ratio of 2.83 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the firm earned $3.50 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.